SCHEMBL3985478

SCHEMBL3985478

Cn1nc(N2CCOCC2)c2c(c(O)c3n2CCN(Cc2ccc(F)cc2)C3=O)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.39
GRM2 Q14416 1/20 0.39
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
CYP1A2 P05177 4/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2C9 P11712 2/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 3/20 0.36
TP53 P04637 1/20 0.35
SRC P12931 1/20 0.35
FLT3 P36888 1/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CB P42338 1/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 5/20 0.35
PKM P14618 3/20 0.35
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985751 0.84 GRM2 (0.45) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL3982142 0.83 KCNH2 (0.42) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL3985740 0.82 MEN1 (0.43) KCNH2GRM2MEN1KMT2ACYP1A2
SCHEMBL3988053 0.79 KCNH2 (0.39) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL1387122 0.75 GRM2 (0.43) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL4749017 0.75 KCNH2 (0.44) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL3983983 0.75 GRM2 (0.44) KCNH2GRM2MEN1KMT2ATP53
SCHEMBL3986546 0.75 SMN1; SMN2 (0.37) CYP1A2CYP3A4CYP2C19CYP2C9HSD17B10
SCHEMBL2895560 0.74 MEN1 (0.47) KCNH2GRM2MEN1KMT2ACYP1A2
SCHEMBL4743833 0.74 KCNH2 (0.41) KCNH2GRM2MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP KCNH2 1197/4885GRM2 4663/4885MEN1 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.